Barclays analyst Stephanie Davis maintains $Evolent Health (EVH.US)$ with a buy rating, and adjusts the target price from $39 to $19.
According to TipRanks data, the analyst has a success rate of 45.2% and a total average return of -4.6% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
Evolent Health's Q3 EBITDA was notably below consensus, primarily due to a considerable rise in Oncology costs, which were experienced both retrospectively and within the quarter. Despite this setback, the company's recent signing of $200M in new run-rate business during Q3 underscores the growing demand for specialty care management.
Evolent Health's third-quarter financial performance was seen as underwhelming. Previous expectations indicated that the company was positioned to recover a significant portion of higher expenses through contractual rate enhancements. Despite this, the market's response implies skepticism regarding the company's capability to reach approximately $300M in EBITDA. Nevertheless, it is considered that the current challenges are atypical, and there is confidence that Evolent's profit margins will stabilize as the negotiated price increments come into play.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
巴克莱银行分析师Stephanie Davis维持$Evolent Health (EVH.US)$买入评级，并将目标价从39美元下调至19美元。
根据TipRanks数据显示，该分析师近一年总胜率为45.2%，总平均回报率为-4.6%。
此外，综合报道，$Evolent Health (EVH.US)$近期主要分析师观点如下：
evolent health的第三季EBITDA明显低于共识，主要是由于肿瘤学成本大幅上升，这种增加需要进行审视且在该季度内发生。尽管遇到了这一挫折，但该公司最近在第三季度签署了20000万元新的业务，突显了专科护理管理需求的增长。
evolent health的第三季财务表现被视为令人失望。之前的预期表明，该公司通过合同费率的提高定位于恢复更大比例的支出。尽管如此，市场的反应暗示了对该公司达到约30000万元EBITDA的能力的怀疑。然而，目前的挑战被认为是非典型的，并且有信心认为随着谈判价格的递增，evolent的利润率将稳定。
提示:
TipRanks为独立第三方，提供金融分析师的分析数据，并计算分析师推荐的平均回报率和胜率。提供的信息并非投资建议，仅供参考。本文不对评级数据和报告的完整性与准确性做出认可、声明或保证。
TipRanks提供每位分析师的星级，分析师星级代表分析师所有推荐的过往表现，通过分析师的总胜率和平均回报率综合计算得出，星星越多，则该分析师过往表现越优异，最高为5颗星。
分析师总胜率为近一年分析师的评级成功次数占总评级次数的比率。评级的成功与否，取决于TipRanks的虚拟投资组合是否从该股票中产生正回报。
总平均回报率为基于分析师的初始评级创建虚拟投资组合，并根据评级变化对组合进行调整，在近一年中该投资组合所获得的回报率。
